Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. We have established R&D collaborations with Shire, Takeda, AstraZeneca, MedImmune and Novartis Option Fund, and have raised $40M in venture financing from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. Heptares is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that modulate historically undruggable or challenging GPCRs. Our integrated discovery platform includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time. Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, autism, anxiety & depression, chronic insomnia, addiction and diabetes. For more information, please visit http://www.heptares.com.
- Langmead, C. et al. (2012) J. Med. Chem. DOI: 10.1021/jm201455y. Published online: January 17, 2012
- Congreve, M. et al. (2012) J. Med. Chem. DOI: 10.1021/jm201376w. Published online: January 5, 2012
- Zhukov, A. et al. (2012) J. Med. Chem., 2011, 54 (13), pp 4312-4323
Contact Information Citigate DeweRogerson (for Heptares) Mark Swallow, Chris Gardner +1 857-222-4586 firstname.lastname@example.org +44 (0)20-7282-2948 email@example.com Heptares Therapeutics Ltd Malcolm Weir, Chief Executive Officer (UK) +44 (0)1707-358-629 firstname.lastname@example.org Dan Grau, President ( USA) +1-857-222-4586 email@example.com
SOURCE Heptares Therapeutics